{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:45:43Z","timestamp":1764510343337,"version":"3.44.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1053\/j.seminhematol.2007.08.007","type":"journal-article","created":{"date-parts":[[2008,1,9]],"date-time":"2008-01-09T19:21:57Z","timestamp":1199906517000},"page":"234-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Autologous Stem Cell Transplantation in Lymphoma"],"prefix":"10.1053","volume":"44","author":[{"given":"Norbert","family":"Schmitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2007.08.007_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/sj.bmt.1705555","article-title":"Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: Focus on increasing use of unrelated donors","volume":"39","author":"Gratwohl","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib3","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib4","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib5","first-page":"630","article-title":"Stanford V and radiotherapy for locally extensive and advanced Hodgkin\u2019s disease: Mature results of a prospective clinical trial","volume":"20","author":"Horning","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib6","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2002.11.107","article-title":"ChlVPP\/EVA hybrid v the weekly VAPEC-B regimen for previously untreated Hodgkin\u2019s disease","volume":"20","author":"Radford","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(88)91477-8","article-title":"Hodgkin\u2019s disease prognosis: a directly predictive equation","volume":"1","author":"Gobbi","year":"1988","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1200\/JCO.1990.8.7.1173","article-title":"Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin\u2019s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy","volume":"8","author":"Straus","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib9","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/0277-5379(91)90231-2","article-title":"A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin\u2019s disease at diagnosis","volume":"27","author":"Proctor","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib10","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2007.08.007_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10428199509052706","article-title":"Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin\u2019s disease?","volume":"15","author":"Hasenclever","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib12","first-page":"99","article-title":"Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin\u2019s disease in first complete remission after MOPP\/ABVD protocol","volume":"8","author":"Carella","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib13","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1200\/JCO.2003.11.103","article-title":"High-dose therapy and autologous stem-cell transplantation v conventional therapy for patients with advanced Hodgkin\u2019s lymphoma responding to front-line therapy","volume":"21","author":"Federico","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib14","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib15","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood.V77.10.2292.2292","article-title":"Outcome of treatment of first relapse of Hodgkin\u2019s disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988","volume":"77","author":"Lohri","year":"1991","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1293::AID-CNCR18>3.0.CO;2-W","article-title":"Analysis of prognostic factors after the first relapse of Hodgkin\u2019s disease in 187 patients","volume":"78","author":"Brice","year":"1996","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bmt.1702796","article-title":"Autotransplants for Hodgkin\u2019s disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR)","volume":"27","author":"Lazarus","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2000.18.2.332","article-title":"Treatment of primary progressive Hodgkin\u2019s and aggressive non-Hodgkin\u2019s lymphoma: Is there a chance for cure?","volume":"18","author":"Josting","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: Results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib20","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: A randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib21","doi-asserted-by":"crossref","first-page":"562s","DOI":"10.1200\/jco.2005.23.16_suppl.562","volume":"23","author":"Schmitz","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2141.2003.04828.x","article-title":"Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease","volume":"124","author":"Moskowitz","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib23","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.1999.17.10.3101","article-title":"High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin\u2019s disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation","volume":"17","author":"Sweetenham","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1999.17.2.534","article-title":"Autotransplants for Hodgkin\u2019s disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry","volume":"17","author":"Lazarus","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.1999.17.1.222","article-title":"Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin\u2019s disease induction failure: A case-control study","volume":"17","author":"Andre","year":"1999","journal-title":"J Clin Oncol"},{"unstructured":"Robinson SP, Sureda A, Canals C, Taghipour G, Russell N, Caballero D, et al: Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin\u2019s disease: Identification of prognostic factors predicting outcome. Blood (submitted)","key":"10.1053\/j.seminhematol.2007.08.007_bib26"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cncr.21587","volume":"106","author":"Kuruvilla","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib28","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","article-title":"Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Baetz","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib30","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bbmt.2005.05.014","article-title":"Ifosfamide, idarubicin, and etoposide in relapsed\/refractory Hodgkin disease or non-Hodgkin lymphoma: A salvage regimen with high response rates before autologous stem cell transplantation","volume":"11","author":"Oyan","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2002-12-3842","article-title":"Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation","volume":"102","author":"Spaepen","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.beha.2004.08.016","article-title":"Monoclonal antibodies in the treatment of indolent lymphomas","volume":"18","author":"Coiffier","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib33","first-page":"104","article-title":"Current status and perspective of antibody therapy in follicular lymphoma","volume":"91","author":"Buske","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib34","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib35","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib36","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.bmt.1702336","article-title":"Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)","volume":"25","author":"Voso","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1034\/j.1600-0609.2000.90114.x","article-title":"Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma","volume":"65","author":"Berglund","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1200\/JCO.1999.17.1.216","article-title":"Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma","volume":"17","author":"Apostolidis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib39","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib40","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib41","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib42","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1023\/A:1008399623564","article-title":"High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol","volume":"11","author":"Brice","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib43","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib44","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/bbmt.2001.v7.pm11400952","article-title":"High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience","volume":"7","author":"Cao","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cncr.22383","article-title":"High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: A study using patients as their own controls","volume":"109","author":"Vignot","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib46","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: Results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2002-06-1793","article-title":"Radioimmunotherapy of non-Hodgkin lymphomas","volume":"101","author":"Cheson","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib48","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.beha.2006.05.002","article-title":"Radioimmunotherapy for B-cell non-Hodgkin lymphoma","volume":"19","author":"Witzig","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib49","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy v conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib50","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib51","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2005.05.117","article-title":"Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin\u2019s lymphoma","volume":"23","author":"Vose","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib52","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab v CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib53","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib54","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high dose therapy in poor risk aggressive non-Hodgkin\u2019s lymphoma: Final analysis of the prospective LNH87-2 protocol\u2014A Groupe d\u2019Etude des Lymphomse de l\u2019Adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib55","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","article-title":"High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma","volume":"336","author":"Gianni","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib56","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.1998.16.8.2796","article-title":"VACOP-B v VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin\u2019s lymphoma: Results of a prospective randomized trial by the Non-Hodgkin\u2019s Lymphoma Cooperative Group","volume":"16","author":"Santini","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib57","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","article-title":"Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support","volume":"350","author":"Milpied","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib58","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/annonc\/mdl153","article-title":"Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: Results of the international randomized phase III trial (MISTRAL)","volume":"17","author":"Betticher","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jnci\/93.1.22","article-title":"Standard chemotherapy with or without high-dose chemotherapy for aggressive non-hodgkin\u2019s lymphoma: Randomized phase III EORTC study","volume":"93","author":"Kluin-Nelemans","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib60","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1200\/JCO.2002.07.075","article-title":"Randomized study to evaluate the use of high-dose therapy as part of primary treatment for \u201caggressive\u201d lymphoma","volume":"20","author":"Kaiser","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib61","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2005-04-1570","article-title":"Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma","volume":"107","author":"Glass","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib62","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2004.12.032","article-title":"Prognostic factors in patients with aggressive non-Hodgkin\u2019s lymphoma treated by front-line autotransplantation after complete remission: A cohort study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"22","author":"Mounier","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib63","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/annonc\/mdh471","article-title":"All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: A matched-control analysis by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)","volume":"15","author":"Mounier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib64","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ctrv.2007.02.002","article-title":"High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma\u2014Results of a comprehensive meta-analysis","volume":"33","author":"Greb","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib65","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib66","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood.V106.11.2068.2068","volume":"106","author":"Tarella","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib67","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood.V108.11.3049.3049","article-title":"Rituximab combined to ACVBP (R-ACVBP) as a new inductive treatment followed by high-dose consolidative autotransplantation (HDC) for poor risk diffuse large B-cell lymphoma (DLBCL) in first line","volume":"108","author":"Belhadj","year":"2006","journal-title":"Blood"},{"unstructured":"Glass B, Kloess M, Reiser M, Freund M, Truemper M, Metzner B. et al: Repeated high-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Leukemia (submitted)","key":"10.1053\/j.seminhematol.2007.08.007_bib68"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib69","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V106.11.677.677","article-title":"Rituximab vs. observation after high dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib71","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib72","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood.V108.11.328.328","article-title":"Rituximab (Mabthera) improves the treatment results of DHAP-VIM-DHAP and ASCT in relapse\/progressive aggressive CD20+ NHL","volume":"108","author":"Vellenga","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib73","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib74","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib75","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3324\/haematol.10608","article-title":"Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: Effects on molecular response and clinical outcome","volume":"92","author":"Dreger","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib76","first-page":"5346","article-title":"Unselected high-risk IPI NHL presented a high early mortality rate in a prospective randomized study comparing conventional chemotherapy and high-dose escalation followed by autologous bone marrow transplantation","volume":"98","author":"De Souza","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib77","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3816\/CLM.2000.n.018","article-title":"CHOP v CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin\u2019s lymphoma","volume":"1","author":"Intragumtornchai","year":"2000","journal-title":"Clin Lymphoma"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib78","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1996.14.2.534","article-title":"High-dose chemotherapy followed by autologous bone marrow transplantation v dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin\u2019s lymphoma with partial response to front-line chemotherapy: A prospective randomized italian multicenter study","volume":"14","author":"Martelli","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib79","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.2003.01.117","article-title":"Early autologous stem-cell transplantation v conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin\u2019s lymphoma: An Italian multicenter randomized trial","volume":"21","author":"Martelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib80","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJM199504203321601","article-title":"Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"332","author":"Verdonck","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib81","first-page":"793","article-title":"High dose sequential chemotherapy with autologous transplantation v dose-dense chemotherapy megaCEOP as first line treatment in poor-prognosis diffuse large ell lymphoma: An \u201cIntergruppo Italiano Linfomi\u201d randomized trial","volume":"90","author":"Vitolo","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib82","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdi399","article-title":"Upfont high-dose sequential therapy (HDS) v VACOP-B with or without HDS in aggressive non-Hodgkin\u2019s lymphoma: Long term results by the NHLCSG","volume":"16","author":"Olivieri","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2007.08.007_bib83","first-page":"11","article-title":"Randomized comparison of frontline alternating chemotherapy (ATT) v brief induction followed by autologous stem cell transplantation (ASCT) for aggressive lymphomas","volume":"102","author":"Rodriguez","year":"2003","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196307001242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196307001242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:19:08Z","timestamp":1758521948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196307001242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0037196307001242"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2007.08.007","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous Stem Cell Transplantation in Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2007.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}